Danaher Corp

DHR

Equity

ISIN null / Valor 923916

New York Stock Exchange, Inc (2025-11-14)

USD 221.210.00%

Danaher Corp
UMushroom community rating:

4.25 2 votes No rating yet

NegativeNeutralPositive

About company

Danaher Corporation is a globally recognized conglomerate with a diverse portfolio that includes a significant presence in the biotechnology sector through its subsidiary, Cytiva. This segment of Danaher's business specializes in providing a comprehensive range of technologies, services, and expertise aimed at supporting the research, development, and manufacturing processes within the biopharmaceutical industry. Cytiva plays a crucial role in facilitating the advancement of therapeutics by offering solutions that enhance the safety and efficiency of developing and commercializing a wide array of medical treatments, including life-saving vaccines, biologic drugs, and innovative cell and gene therapies. Through its focus on innovation and customer support, Danaher, via Cytiva, contributes significantly to the progress of healthcare and the availability of advanced therapeutic options.

Summarized from source with an LLMView SourceSector: Industrials

Exceeded Expectations

Danaher’s strong execution using the Danaher Business System, coupled with significant growth in the Bioprocessing business, enabled the company to surpass its financial expectations for the quarter ended June 27, 2025.

Robust Growth in Bioprocessing

The Bioprocessing segment demonstrated another quarter of robust growth, contributing significantly to the overall financial performance and reinforcing Danaher’s position in the life sciences and diagnostics market.

Increased Earnings Guidance

For the full year 2025, Danaher has raised its adjusted diluted net earnings per common share guidance to a range of $7.70 to $7.80, up from the previous guidance of $7.60 to $7.75, reflecting confidence in continued financial strength.

Positive Full Year Revenue Outlook

The company maintains its expectation for non-GAAP core revenue to grow approximately 3% year-over-year for the full year 2025, supported by disciplined cost management and a differentiated portfolio.

Summarized from source with an LLMView Source

Key figures

-7.59%1Y

-6.35%3Y

6.43%5Y

Performance

33.0%1Y

29.8%3Y

29.3%5Y

Volatility